Russian medics and engineers report about finishing preclinical trial stage of a new candidate drug for treating hepatitis C and starting clinical trials.
      
      The ID-12 chemical compound is an original low molecular inhibitor, which blocks initial stages of virus expansion. The molecule was developed within a public private partnership, and it took its designers three years to test the series of potential curing agents to find the ID-12.
      
      First stage of clinical trials, during which drug’s safety and pharmacokinetic properties will be determined, is scheduled for winter 2009 and will take place in Russian Federation.
      
      Source: Science & Technologies